{"gene":"ADRA1A","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2022,"finding":"ADRA1A physically and functionally couples with Gαq in adipocytes to promote thermogenesis through the futile creatine cycle, requiring effector proteins creatine kinase B (CKB) and tissue-non-specific alkaline phosphatase (TNAP); combined Gαq and Gαs signaling selectively in adipocytes drives whole-body energy expenditure in a CKB-dependent manner.","method":"Co-immunoprecipitation, genetic loss-of-function (adipocyte-selective knockouts), in vivo energy expenditure measurements, pharmacological receptor subtype dissection","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (Co-IP for physical coupling, adipocyte-selective KO for functional requirement of CKB, pharmacology), replicated across multiple experimental contexts","pmids":["36344764"],"is_preprint":false},{"year":2025,"finding":"In the lacrimal gland, sympathetic noradrenaline activates Adra1a in acinar and myoepithelial cells to regulate mitochondrial Ucp2 and suppress tear secretion; pharmacological, surgical, and genetic blockade of Adra1a increases tear secretion and alleviates dry eye signs.","method":"Pharmacological blockade (silodosin, tamsulosin), surgical sympathectomy, genetic knockout, immunofluorescence localization in lacrimal gland cells, dry eye mouse models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — three independent intervention approaches (pharmacological, surgical, genetic) with consistent phenotypic readouts and mechanistic link to Ucp2","pmids":["40473608"],"is_preprint":false},{"year":2024,"finding":"Cortical astrocytes express Adra1a adrenergic receptors through which norepinephrine elicits sustained increases in intracellular calcium; this calcium signal invokes purinergic pathways that signal to neurons via adenosine A1 receptors to mediate post-reinforcement behavioral improvement in learning.","method":"Chemogenetic blockade of astrocytic calcium, pharmacological A1-receptor blockade, calcium imaging, behavioral assays, prefrontal cortex neuronal encoding analysis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods in a single preprint lab study; awaits peer review","pmids":["bio_10.1101_2024.10.24.620009"],"is_preprint":true},{"year":2021,"finding":"miR-3682 targets and negatively regulates ADRA1A (confirmed by dual-luciferase reporter assay), and ADRA1A loss inactivates AMPK signaling; knockdown of ADRA1A partially offsets the inhibitory effect of miR-3682 inhibitor on HCC cell growth and mobility, placing ADRA1A upstream of AMPK in this pathway.","method":"Dual-luciferase reporter assay, Western blot of AMPK pathway proteins, siRNA knockdown, cell viability/migration assays","journal":"Annals of hepatology","confidence":"Medium","confidence_rationale":"Tier 2/3 — luciferase reporter confirms direct miR-3682 targeting, epistasis via knockdown rescue experiment; single lab","pmids":["34706275"],"is_preprint":false},{"year":2023,"finding":"Decreased Adra1a expression in the heart of pregnancy-associated hypertensive mice exacerbates Ang II-driven cardiac hypertrophy; Adra1a-deficient PAH mice show more severe hypertrophy than PAH mice with intact Adra1a, and Adra1a expression is regulated by the renin-angiotensin system.","method":"Comprehensive cardiac gene expression analysis, Adra1a knockout in PAH mouse model, cardiac hypertrophy phenotypic readout","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with defined cardiac hypertrophy phenotype in a disease model; single lab","pmids":["36736425"],"is_preprint":false},{"year":2017,"finding":"miR-19b and miR-16 cooperatively target ADRA1A (confirmed by miRNA inhibitor rescue experiments); inhibition of these miRNAs increases ADRA1A expression and decreases caspase 3/7 activation, reducing myocardial apoptosis and fibrosis in a DOCA-induced hypertensive heart disease mouse model.","method":"miRNA inhibitor/antagomir treatment, RT-PCR and Western blot for ADRA1A expression, caspase 3/7 activity assay, cardiac fibrosis histology, in vivo mouse model","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 3 — functional rescue with miRNA inhibitors links miR-19b/16 to ADRA1A; direct 3'UTR targeting not formally validated by luciferase in this paper; single lab","pmids":["28531963"],"is_preprint":false},{"year":2024,"finding":"Leonurine improves hepatic lipid metabolism in NAFLD through the ADRA1a/AMPK/SCD1 axis, verified by molecular docking and Western blot of AMPK signaling components, with ADRA1a acting as the upstream target.","method":"Molecular docking, Western blot, transcriptomic and lipidomic analysis, HFHSD mouse model","journal":"International journal of molecular sciences","confidence":"Low","confidence_rationale":"Tier 3 — molecular docking is computational; Western blot evidence for pathway; single lab without direct ADRA1a loss-of-function validation","pmids":["39409181"],"is_preprint":false},{"year":2023,"finding":"Circ_0080608 acts as a competing endogenous RNA sponging miR-661, which directly targets the 3' UTR of ADRA1A (confirmed by dual-luciferase reporter and RIP assay); ADRA1A overexpression suppresses lung cancer cell proliferation and migration, and miR-661 re-introduction reduces ADRA1A levels and reverses this suppression.","method":"Dual-luciferase reporter assay, RIP assay, Western blot, CCK-8/colony formation/Transwell assays, in vivo tumor model","journal":"Hormone and metabolic research","confidence":"Medium","confidence_rationale":"Tier 2/3 — direct binding confirmed by luciferase and RIP; functional epistasis shown by miR-661 re-introduction; single lab","pmids":["37820700"],"is_preprint":false},{"year":2010,"finding":"Alternative transcripts of ADRA1A are generated by at least four mechanisms: transposable element (TE) integration (AluSc, L1MC5, MIR3) creating alternative last exons, differential promoter usage, substitution of 3' splice sites during primate evolution, and an unknown mechanism; six alternative transcripts were experimentally validated by RT-PCR and sequencing.","method":"RT-PCR, sequencing, in silico analysis of splice variants","journal":"Genes & genetic systems","confidence":"Medium","confidence_rationale":"Tier 2 — direct experimental validation of transcript variants by RT-PCR and sequencing; single lab","pmids":["20410666"],"is_preprint":false},{"year":2025,"finding":"Irisin regulates energy metabolism in hypoxic cardiomyocytes via the ADRA1A-AMPK signaling pathway; AMPK inhibitor (Compound C) diminishes the protective effects of Irisin on mitochondrial membrane potential and ATP production, and ADRA1A is identified as an upstream regulator in this pathway.","method":"Western blot, qPCR, mitochondrial membrane potential assay, ATP production assay, aortic constriction CHF mouse model, pharmacological inhibition","journal":"European journal of medical research","confidence":"Low","confidence_rationale":"Tier 3 — ADRA1A-AMPK link inferred from pathway analysis and Compound C inhibition; direct manipulation of ADRA1A not shown; single lab","pmids":["40660392"],"is_preprint":false}],"current_model":"ADRA1A (α1A-adrenergic receptor) is a Gαq-coupled GPCR that, upon noradrenaline stimulation, activates downstream signaling through the futile creatine cycle (CKB/TNAP) in adipocytes to drive thermogenesis, suppresses tear secretion in lacrimal gland acinar and myoepithelial cells via mitochondrial Ucp2, elicits sustained astrocytic calcium increases that invoke purinergic-neuronal signaling to mediate learning, and regulates AMPK pathway activity in hepatic and cardiac contexts; its expression is controlled by promoter methylation, miRNAs (miR-19b, miR-16, miR-661, miR-3682), and the renin-angiotensin system, and it produces multiple alternatively spliced isoforms through TE integration, differential promoter usage, and splice-site variation."},"narrative":{"teleology":[{"year":2010,"claim":"Establishing that ADRA1A generates transcript diversity through TE integration and splice-site evolution answered how a single GPCR gene produces functionally distinct isoforms across tissues.","evidence":"RT-PCR and sequencing validation of six alternative transcripts arising from AluSc/L1MC5/MIR3 integration, differential promoters, and alternative 3' splice sites in human tissues","pmids":["20410666"],"confidence":"Medium","gaps":["Functional consequences of individual isoforms not characterized","Tissue-specific isoform expression profiles not systematically quantified","Protein-level validation of alternative isoforms not performed"]},{"year":2017,"claim":"Demonstration that miR-19b and miR-16 cooperatively suppress ADRA1A expression to promote cardiac apoptosis and fibrosis revealed a post-transcriptional regulatory axis for receptor abundance in hypertensive heart disease.","evidence":"miRNA inhibitor rescue in DOCA-induced hypertensive mice showing increased ADRA1A protein and decreased caspase 3/7 activity and fibrosis","pmids":["28531963"],"confidence":"Medium","gaps":["Direct 3'UTR targeting by miR-19b/16 not validated by luciferase reporter in this study","Mechanism linking restored ADRA1A to anti-apoptotic signaling not delineated","Single disease model"]},{"year":2021,"claim":"Identification of miR-3682 as a direct negative regulator of ADRA1A and placement of ADRA1A upstream of AMPK signaling in hepatocellular carcinoma cells established ADRA1A as a signaling node in the AMPK pathway beyond its classical Gαq coupling.","evidence":"Dual-luciferase reporter assay confirming miR-3682 targeting of ADRA1A 3'UTR, siRNA knockdown epistasis, and Western blot of AMPK pathway in HCC cells","pmids":["34706275"],"confidence":"Medium","gaps":["ADRA1A-AMPK coupling mechanism (direct vs. indirect) not resolved","In vivo validation in liver tissue not performed","Single cancer cell line context"]},{"year":2022,"claim":"Physical coupling of ADRA1A to Gαq in adipocytes and functional requirement of the futile creatine cycle (CKB/TNAP) for receptor-driven thermogenesis provided the first tissue-specific effector pathway linking α1A-adrenergic signaling to whole-body energy expenditure.","evidence":"Co-immunoprecipitation of ADRA1A-Gαq, adipocyte-selective CKB knockout abolishing energy expenditure, and pharmacological receptor subtype dissection in mice","pmids":["36344764"],"confidence":"High","gaps":["Whether Gαq-creatine cycle coupling occurs in non-adipocyte tissues unknown","Structural basis of ADRA1A-Gαq selectivity not resolved","Human translational relevance not demonstrated"]},{"year":2023,"claim":"Loss of Adra1a in pregnancy-associated hypertensive mice exacerbated Ang II-driven cardiac hypertrophy, establishing a cardioprotective function for Adra1a and its regulation by the renin-angiotensin system.","evidence":"Adra1a knockout in PAH mouse model with cardiac hypertrophy phenotyping and gene expression analysis","pmids":["36736425"],"confidence":"Medium","gaps":["Downstream signaling pathway mediating cardioprotection not identified","Whether RAS regulation of Adra1a is transcriptional or post-transcriptional not determined","Relevance to human preeclampsia not tested"]},{"year":2023,"claim":"Validation that miR-661 directly targets the ADRA1A 3'UTR and that ADRA1A overexpression suppresses lung cancer cell proliferation added another miRNA regulatory axis and suggested a tumor-suppressive role for ADRA1A in a non-cardiovascular context.","evidence":"Dual-luciferase reporter and RIP assay confirming miR-661 binding, epistasis by miR-661 re-introduction reversing ADRA1A-mediated growth suppression, in vivo tumor model","pmids":["37820700"],"confidence":"Medium","gaps":["Mechanism by which ADRA1A suppresses proliferation in lung cancer cells unknown","Whether this is ligand-dependent or constitutive activity not addressed","Single cell line and xenograft model"]},{"year":2025,"claim":"Demonstration that ADRA1A in lacrimal gland acinar and myoepithelial cells regulates mitochondrial Ucp2 to suppress tear secretion, and that its blockade rescues dry eye, defined an unexpected secretory-regulatory function for the receptor.","evidence":"Pharmacological blockade (silodosin, tamsulosin), surgical sympathectomy, and genetic knockout in dry eye mouse models with immunofluorescence localization","pmids":["40473608"],"confidence":"High","gaps":["How ADRA1A-Gαq signaling regulates Ucp2 expression or activity not elucidated","Human clinical validation pending","Whether other α1-adrenergic subtypes contribute in the lacrimal gland not fully excluded"]},{"year":null,"claim":"The precise signaling intermediates linking ADRA1A to AMPK activation, the structural basis of ADRA1A's tissue-specific effector coupling (creatine cycle in adipocytes, Ucp2 in lacrimal gland), and the functional significance of its multiple splice isoforms remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of ADRA1A-Gαq complex","ADRA1A-AMPK signaling intermediates unidentified","Functional roles of individual splice isoforms not tested","In vivo relevance of miRNA regulation in non-disease physiology not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,2]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,2]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,3,4]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,3,6]}],"complexes":[],"partners":["GNAQ","CKB","ALPL","UCP2","PRKAA1"],"other_free_text":[]},"mechanistic_narrative":"ADRA1A (α1A-adrenergic receptor) is a Gαq-coupled G protein-coupled receptor activated by noradrenaline that transduces sympathetic signals into diverse tissue-specific cellular responses, including thermogenesis, secretory regulation, calcium-dependent gliotransmission, and metabolic homeostasis. In adipocytes, ADRA1A physically couples to Gαq to drive energy expenditure through the futile creatine cycle requiring creatine kinase B (CKB) and tissue-non-specific alkaline phosphatase (TNAP) [PMID:36344764]; in lacrimal gland acinar and myoepithelial cells, it suppresses tear secretion via mitochondrial Ucp2, and its pharmacological, surgical, or genetic blockade alleviates dry eye [PMID:40473608]. ADRA1A functions upstream of AMPK signaling in hepatic and cardiac contexts and exerts a cardioprotective role, as Adra1a deficiency exacerbates angiotensin II-driven cardiac hypertrophy in pregnancy-associated hypertensive mice [PMID:36736425, PMID:34706275]. ADRA1A expression is post-transcriptionally regulated by multiple miRNAs including miR-19b, miR-16, miR-661, and miR-3682 [PMID:28531963, PMID:37820700, PMID:34706275], and the gene produces multiple alternatively spliced isoforms generated through transposable element integration, differential promoter usage, and splice-site variation [PMID:20410666]."},"prefetch_data":{"uniprot":{"accession":"P35348","full_name":"Alpha-1A adrenergic receptor","aliases":["Alpha-1A adrenoreceptor","Alpha-1A adrenoceptor","Alpha-1C adrenergic receptor","Alpha-adrenergic receptor 1c"],"length_aa":466,"mass_kda":51.5,"function":"Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C (PubMed:37563160). ADRA1A binds the catecholamine ligands norepinephrine and epinephrine (PubMed:18802028, PubMed:37563160, PubMed:7815325, PubMed:8024574, PubMed:8183249, PubMed:8832064). Can also couple to G(14) protein (By similarity). Nuclear ADRA1A forms heterooligomers with ADRA1B to regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes (PubMed:18802028, PubMed:22120526). At the plasma membrane, ADRA1A interacts with CAVIN4/MURC to regulates ERK activation in cardiomyocytes, contributing to the regulation of cardiac hypertrophy (PubMed:24567387). Additionally, functions as a vasopressor in resistance arteries and plays a role in maintaining normal arterial blood pressure (By similarity)","subcellular_location":"Nucleus membrane; Cell membrane; Cytoplasm; Membrane, caveola","url":"https://www.uniprot.org/uniprotkb/P35348/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADRA1A","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADRA1A","total_profiled":1310},"omim":[{"mim_id":"604406","title":"GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-13; GNA13","url":"https://www.omim.org/entry/604406"},{"mim_id":"604394","title":"GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-12; GNA12","url":"https://www.omim.org/entry/604394"},{"mim_id":"190196","title":"TRANSGLUTAMINASE 2; TGM2","url":"https://www.omim.org/entry/190196"},{"mim_id":"104221","title":"ALPHA-1A-ADRENERGIC RECEPTOR; ADRA1A","url":"https://www.omim.org/entry/104221"},{"mim_id":"104219","title":"ALPHA-1D-ADRENERGIC RECEPTOR; ADRA1D","url":"https://www.omim.org/entry/104219"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":20.5},{"tissue":"liver","ntpm":56.2}],"url":"https://www.proteinatlas.org/search/ADRA1A"},"hgnc":{"alias_symbol":["ADRA1L1"],"prev_symbol":["ADRA1C"]},"alphafold":{"accession":"P25100","domains":[{"cath_id":"1.20.1070.10","chopping":"91-297_333-425","consensus_level":"medium","plddt":86.0404,"start":91,"end":425}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P25100","model_url":"https://alphafold.ebi.ac.uk/files/AF-P25100-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P25100-F1-predicted_aligned_error_v6.png","plddt_mean":64.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADRA1A","jax_strain_url":"https://www.jax.org/strain/search?query=ADRA1A"},"sequence":{"accession":"P25100","fasta_url":"https://rest.uniprot.org/uniprotkb/P25100.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P25100/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P25100"}},"corpus_meta":[{"pmid":"36344764","id":"PMC_36344764","title":"ADRA1A-Gαq signalling potentiates adipocyte thermogenesis through CKB and TNAP.","date":"2022","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36344764","citation_count":46,"is_preprint":false},{"pmid":"19352218","id":"PMC_19352218","title":"Candidate gene analysis in an on-going genome-wide association study of attention-deficit hyperactivity disorder: suggestive association signals in ADRA1A.","date":"2009","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19352218","citation_count":30,"is_preprint":false},{"pmid":"31933413","id":"PMC_31933413","title":"Promoter aberrant methylation status of ADRA1A is associated with hepatocellular carcinoma.","date":"2020","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/31933413","citation_count":25,"is_preprint":false},{"pmid":"19918262","id":"PMC_19918262","title":"ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics.","date":"2009","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/19918262","citation_count":21,"is_preprint":false},{"pmid":"28531963","id":"PMC_28531963","title":"MiR-19b and miR-16 cooperatively signaling target the regulator ADRA1A in Hypertensive heart disease.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28531963","citation_count":20,"is_preprint":false},{"pmid":"22037178","id":"PMC_22037178","title":"Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia.","date":"2011","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/22037178","citation_count":19,"is_preprint":false},{"pmid":"15136785","id":"PMC_15136785","title":"A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH.","date":"2004","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/15136785","citation_count":17,"is_preprint":false},{"pmid":"21519279","id":"PMC_21519279","title":"Association between ADRA1A gene and the metabolic syndrome: candidate genes and functional counterpart in the PAMELA population.","date":"2011","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/21519279","citation_count":16,"is_preprint":false},{"pmid":"34706275","id":"PMC_34706275","title":"MiR-3682 promotes the progression of hepatocellular carcinoma (HCC) via inactivating AMPK signaling by targeting ADRA1A.","date":"2021","source":"Annals of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34706275","citation_count":13,"is_preprint":false},{"pmid":"39409181","id":"PMC_39409181","title":"Leonurine Inhibits Hepatic Lipid Synthesis to Ameliorate NAFLD via the ADRA1a/AMPK/SCD1 Axis.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39409181","citation_count":8,"is_preprint":false},{"pmid":"40473608","id":"PMC_40473608","title":"A gatekeeper sympathetic control of lacrimal tear secretion and dry eye onset through the NA-Adra1a-Ucp2 pathway.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40473608","citation_count":6,"is_preprint":false},{"pmid":"17408692","id":"PMC_17408692","title":"No association found between the promoter variants of ADRA1A and schizophrenia in the Chinese population.","date":"2007","source":"Journal of psychiatric research","url":"https://pubmed.ncbi.nlm.nih.gov/17408692","citation_count":6,"is_preprint":false},{"pmid":"36736425","id":"PMC_36736425","title":"Increased angiotensin II coupled with decreased Adra1a expression enhances cardiac hypertrophy in pregnancy-associated hypertensive mice.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36736425","citation_count":4,"is_preprint":false},{"pmid":"27379509","id":"PMC_27379509","title":"The α-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals.","date":"2016","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/27379509","citation_count":4,"is_preprint":false},{"pmid":"35964682","id":"PMC_35964682","title":"Hypermethylation in the promoter region of the ADRA1A gene is associated with opioid use disorder in Han Chinese.","date":"2022","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/35964682","citation_count":3,"is_preprint":false},{"pmid":"20410666","id":"PMC_20410666","title":"Four different ways of alternative transcripts generation mechanism in ADRA1A gene.","date":"2010","source":"Genes & genetic systems","url":"https://pubmed.ncbi.nlm.nih.gov/20410666","citation_count":3,"is_preprint":false},{"pmid":"37820700","id":"PMC_37820700","title":"Hsa_circ_0080608 Attenuates Lung Cancer Progression by Functioning as a Competitive Endogenous RNA to Regulate the miR-661/ADRA1A Pathway.","date":"2023","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/37820700","citation_count":2,"is_preprint":false},{"pmid":"36012699","id":"PMC_36012699","title":"Vascular Reactions of the Diving Reflex in Men and Women Carrying Different ADRA1A Genotypes.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36012699","citation_count":2,"is_preprint":false},{"pmid":"19102884","id":"PMC_19102884","title":"[Association between ADRA1A gene polymorphism and autoantibodies against the alpha1-adrenergic receptor in hypertensive patients.].","date":"2008","source":"Zhonghua xin xue guan bing za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/19102884","citation_count":2,"is_preprint":false},{"pmid":"40660392","id":"PMC_40660392","title":"Irisin regulates cardiac myocyte energy metabolic remodeling involved the ADRA1A-AMPK signaling pathwayng pathway.","date":"2025","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/40660392","citation_count":1,"is_preprint":false},{"pmid":"41473249","id":"PMC_41473249","title":"Prostogrit mitigates testosterone/estradiol induced prostatic enlargement/remodeling in rat model of benign prostatic hyperplasia and fine-tunes prostatic expression of Adra1a and Il6 genes.","date":"2025","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/41473249","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.10.24.620009","title":"Cortical norepinephrine-astrocyte signaling critically mediates learned behavior","date":"2024-10-24","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.24.620009","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12673,"output_tokens":2558,"usd":0.038194},"stage2":{"model":"claude-opus-4-6","input_tokens":5881,"output_tokens":2294,"usd":0.130133},"total_usd":0.168327,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2022,\n      \"finding\": \"ADRA1A physically and functionally couples with Gαq in adipocytes to promote thermogenesis through the futile creatine cycle, requiring effector proteins creatine kinase B (CKB) and tissue-non-specific alkaline phosphatase (TNAP); combined Gαq and Gαs signaling selectively in adipocytes drives whole-body energy expenditure in a CKB-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, genetic loss-of-function (adipocyte-selective knockouts), in vivo energy expenditure measurements, pharmacological receptor subtype dissection\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Co-IP for physical coupling, adipocyte-selective KO for functional requirement of CKB, pharmacology), replicated across multiple experimental contexts\",\n      \"pmids\": [\"36344764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In the lacrimal gland, sympathetic noradrenaline activates Adra1a in acinar and myoepithelial cells to regulate mitochondrial Ucp2 and suppress tear secretion; pharmacological, surgical, and genetic blockade of Adra1a increases tear secretion and alleviates dry eye signs.\",\n      \"method\": \"Pharmacological blockade (silodosin, tamsulosin), surgical sympathectomy, genetic knockout, immunofluorescence localization in lacrimal gland cells, dry eye mouse models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — three independent intervention approaches (pharmacological, surgical, genetic) with consistent phenotypic readouts and mechanistic link to Ucp2\",\n      \"pmids\": [\"40473608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cortical astrocytes express Adra1a adrenergic receptors through which norepinephrine elicits sustained increases in intracellular calcium; this calcium signal invokes purinergic pathways that signal to neurons via adenosine A1 receptors to mediate post-reinforcement behavioral improvement in learning.\",\n      \"method\": \"Chemogenetic blockade of astrocytic calcium, pharmacological A1-receptor blockade, calcium imaging, behavioral assays, prefrontal cortex neuronal encoding analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in a single preprint lab study; awaits peer review\",\n      \"pmids\": [\"bio_10.1101_2024.10.24.620009\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-3682 targets and negatively regulates ADRA1A (confirmed by dual-luciferase reporter assay), and ADRA1A loss inactivates AMPK signaling; knockdown of ADRA1A partially offsets the inhibitory effect of miR-3682 inhibitor on HCC cell growth and mobility, placing ADRA1A upstream of AMPK in this pathway.\",\n      \"method\": \"Dual-luciferase reporter assay, Western blot of AMPK pathway proteins, siRNA knockdown, cell viability/migration assays\",\n      \"journal\": \"Annals of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — luciferase reporter confirms direct miR-3682 targeting, epistasis via knockdown rescue experiment; single lab\",\n      \"pmids\": [\"34706275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Decreased Adra1a expression in the heart of pregnancy-associated hypertensive mice exacerbates Ang II-driven cardiac hypertrophy; Adra1a-deficient PAH mice show more severe hypertrophy than PAH mice with intact Adra1a, and Adra1a expression is regulated by the renin-angiotensin system.\",\n      \"method\": \"Comprehensive cardiac gene expression analysis, Adra1a knockout in PAH mouse model, cardiac hypertrophy phenotypic readout\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined cardiac hypertrophy phenotype in a disease model; single lab\",\n      \"pmids\": [\"36736425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-19b and miR-16 cooperatively target ADRA1A (confirmed by miRNA inhibitor rescue experiments); inhibition of these miRNAs increases ADRA1A expression and decreases caspase 3/7 activation, reducing myocardial apoptosis and fibrosis in a DOCA-induced hypertensive heart disease mouse model.\",\n      \"method\": \"miRNA inhibitor/antagomir treatment, RT-PCR and Western blot for ADRA1A expression, caspase 3/7 activity assay, cardiac fibrosis histology, in vivo mouse model\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional rescue with miRNA inhibitors links miR-19b/16 to ADRA1A; direct 3'UTR targeting not formally validated by luciferase in this paper; single lab\",\n      \"pmids\": [\"28531963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Leonurine improves hepatic lipid metabolism in NAFLD through the ADRA1a/AMPK/SCD1 axis, verified by molecular docking and Western blot of AMPK signaling components, with ADRA1a acting as the upstream target.\",\n      \"method\": \"Molecular docking, Western blot, transcriptomic and lipidomic analysis, HFHSD mouse model\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — molecular docking is computational; Western blot evidence for pathway; single lab without direct ADRA1a loss-of-function validation\",\n      \"pmids\": [\"39409181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Circ_0080608 acts as a competing endogenous RNA sponging miR-661, which directly targets the 3' UTR of ADRA1A (confirmed by dual-luciferase reporter and RIP assay); ADRA1A overexpression suppresses lung cancer cell proliferation and migration, and miR-661 re-introduction reduces ADRA1A levels and reverses this suppression.\",\n      \"method\": \"Dual-luciferase reporter assay, RIP assay, Western blot, CCK-8/colony formation/Transwell assays, in vivo tumor model\",\n      \"journal\": \"Hormone and metabolic research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — direct binding confirmed by luciferase and RIP; functional epistasis shown by miR-661 re-introduction; single lab\",\n      \"pmids\": [\"37820700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Alternative transcripts of ADRA1A are generated by at least four mechanisms: transposable element (TE) integration (AluSc, L1MC5, MIR3) creating alternative last exons, differential promoter usage, substitution of 3' splice sites during primate evolution, and an unknown mechanism; six alternative transcripts were experimentally validated by RT-PCR and sequencing.\",\n      \"method\": \"RT-PCR, sequencing, in silico analysis of splice variants\",\n      \"journal\": \"Genes & genetic systems\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct experimental validation of transcript variants by RT-PCR and sequencing; single lab\",\n      \"pmids\": [\"20410666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Irisin regulates energy metabolism in hypoxic cardiomyocytes via the ADRA1A-AMPK signaling pathway; AMPK inhibitor (Compound C) diminishes the protective effects of Irisin on mitochondrial membrane potential and ATP production, and ADRA1A is identified as an upstream regulator in this pathway.\",\n      \"method\": \"Western blot, qPCR, mitochondrial membrane potential assay, ATP production assay, aortic constriction CHF mouse model, pharmacological inhibition\",\n      \"journal\": \"European journal of medical research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — ADRA1A-AMPK link inferred from pathway analysis and Compound C inhibition; direct manipulation of ADRA1A not shown; single lab\",\n      \"pmids\": [\"40660392\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADRA1A (α1A-adrenergic receptor) is a Gαq-coupled GPCR that, upon noradrenaline stimulation, activates downstream signaling through the futile creatine cycle (CKB/TNAP) in adipocytes to drive thermogenesis, suppresses tear secretion in lacrimal gland acinar and myoepithelial cells via mitochondrial Ucp2, elicits sustained astrocytic calcium increases that invoke purinergic-neuronal signaling to mediate learning, and regulates AMPK pathway activity in hepatic and cardiac contexts; its expression is controlled by promoter methylation, miRNAs (miR-19b, miR-16, miR-661, miR-3682), and the renin-angiotensin system, and it produces multiple alternatively spliced isoforms through TE integration, differential promoter usage, and splice-site variation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ADRA1A (α1A-adrenergic receptor) is a Gαq-coupled G protein-coupled receptor activated by noradrenaline that transduces sympathetic signals into diverse tissue-specific cellular responses, including thermogenesis, secretory regulation, calcium-dependent gliotransmission, and metabolic homeostasis. In adipocytes, ADRA1A physically couples to Gαq to drive energy expenditure through the futile creatine cycle requiring creatine kinase B (CKB) and tissue-non-specific alkaline phosphatase (TNAP) [PMID:36344764]; in lacrimal gland acinar and myoepithelial cells, it suppresses tear secretion via mitochondrial Ucp2, and its pharmacological, surgical, or genetic blockade alleviates dry eye [PMID:40473608]. ADRA1A functions upstream of AMPK signaling in hepatic and cardiac contexts and exerts a cardioprotective role, as Adra1a deficiency exacerbates angiotensin II-driven cardiac hypertrophy in pregnancy-associated hypertensive mice [PMID:36736425, PMID:34706275]. ADRA1A expression is post-transcriptionally regulated by multiple miRNAs including miR-19b, miR-16, miR-661, and miR-3682 [PMID:28531963, PMID:37820700, PMID:34706275], and the gene produces multiple alternatively spliced isoforms generated through transposable element integration, differential promoter usage, and splice-site variation [PMID:20410666].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Establishing that ADRA1A generates transcript diversity through TE integration and splice-site evolution answered how a single GPCR gene produces functionally distinct isoforms across tissues.\",\n      \"evidence\": \"RT-PCR and sequencing validation of six alternative transcripts arising from AluSc/L1MC5/MIR3 integration, differential promoters, and alternative 3' splice sites in human tissues\",\n      \"pmids\": [\"20410666\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequences of individual isoforms not characterized\", \"Tissue-specific isoform expression profiles not systematically quantified\", \"Protein-level validation of alternative isoforms not performed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstration that miR-19b and miR-16 cooperatively suppress ADRA1A expression to promote cardiac apoptosis and fibrosis revealed a post-transcriptional regulatory axis for receptor abundance in hypertensive heart disease.\",\n      \"evidence\": \"miRNA inhibitor rescue in DOCA-induced hypertensive mice showing increased ADRA1A protein and decreased caspase 3/7 activity and fibrosis\",\n      \"pmids\": [\"28531963\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct 3'UTR targeting by miR-19b/16 not validated by luciferase reporter in this study\", \"Mechanism linking restored ADRA1A to anti-apoptotic signaling not delineated\", \"Single disease model\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of miR-3682 as a direct negative regulator of ADRA1A and placement of ADRA1A upstream of AMPK signaling in hepatocellular carcinoma cells established ADRA1A as a signaling node in the AMPK pathway beyond its classical Gαq coupling.\",\n      \"evidence\": \"Dual-luciferase reporter assay confirming miR-3682 targeting of ADRA1A 3'UTR, siRNA knockdown epistasis, and Western blot of AMPK pathway in HCC cells\",\n      \"pmids\": [\"34706275\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"ADRA1A-AMPK coupling mechanism (direct vs. indirect) not resolved\", \"In vivo validation in liver tissue not performed\", \"Single cancer cell line context\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Physical coupling of ADRA1A to Gαq in adipocytes and functional requirement of the futile creatine cycle (CKB/TNAP) for receptor-driven thermogenesis provided the first tissue-specific effector pathway linking α1A-adrenergic signaling to whole-body energy expenditure.\",\n      \"evidence\": \"Co-immunoprecipitation of ADRA1A-Gαq, adipocyte-selective CKB knockout abolishing energy expenditure, and pharmacological receptor subtype dissection in mice\",\n      \"pmids\": [\"36344764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Gαq-creatine cycle coupling occurs in non-adipocyte tissues unknown\", \"Structural basis of ADRA1A-Gαq selectivity not resolved\", \"Human translational relevance not demonstrated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Loss of Adra1a in pregnancy-associated hypertensive mice exacerbated Ang II-driven cardiac hypertrophy, establishing a cardioprotective function for Adra1a and its regulation by the renin-angiotensin system.\",\n      \"evidence\": \"Adra1a knockout in PAH mouse model with cardiac hypertrophy phenotyping and gene expression analysis\",\n      \"pmids\": [\"36736425\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream signaling pathway mediating cardioprotection not identified\", \"Whether RAS regulation of Adra1a is transcriptional or post-transcriptional not determined\", \"Relevance to human preeclampsia not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Validation that miR-661 directly targets the ADRA1A 3'UTR and that ADRA1A overexpression suppresses lung cancer cell proliferation added another miRNA regulatory axis and suggested a tumor-suppressive role for ADRA1A in a non-cardiovascular context.\",\n      \"evidence\": \"Dual-luciferase reporter and RIP assay confirming miR-661 binding, epistasis by miR-661 re-introduction reversing ADRA1A-mediated growth suppression, in vivo tumor model\",\n      \"pmids\": [\"37820700\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ADRA1A suppresses proliferation in lung cancer cells unknown\", \"Whether this is ligand-dependent or constitutive activity not addressed\", \"Single cell line and xenograft model\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstration that ADRA1A in lacrimal gland acinar and myoepithelial cells regulates mitochondrial Ucp2 to suppress tear secretion, and that its blockade rescues dry eye, defined an unexpected secretory-regulatory function for the receptor.\",\n      \"evidence\": \"Pharmacological blockade (silodosin, tamsulosin), surgical sympathectomy, and genetic knockout in dry eye mouse models with immunofluorescence localization\",\n      \"pmids\": [\"40473608\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ADRA1A-Gαq signaling regulates Ucp2 expression or activity not elucidated\", \"Human clinical validation pending\", \"Whether other α1-adrenergic subtypes contribute in the lacrimal gland not fully excluded\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The precise signaling intermediates linking ADRA1A to AMPK activation, the structural basis of ADRA1A's tissue-specific effector coupling (creatine cycle in adipocytes, Ucp2 in lacrimal gland), and the functional significance of its multiple splice isoforms remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of ADRA1A-Gαq complex\", \"ADRA1A-AMPK signaling intermediates unidentified\", \"Functional roles of individual splice isoforms not tested\", \"In vivo relevance of miRNA regulation in non-disease physiology not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 3, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GNAQ\",\n      \"CKB\",\n      \"ALPL\",\n      \"UCP2\",\n      \"PRKAA1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}